Fexofenadine: A new generation of antihistamines?;Fexofenadin: Vertreter einer neuen antihistaminika-generation?

Allergologie

Volumn 21, Issue 4, 1998, Pages

  Klimek, Ludger ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Antihistaminics; Fexofenadine

Indexed keywords

ANTIHISTAMINIC AGENT; FEXOFENADINE; HISTAMINE H1 RECEPTOR ANTAGONIST; TERFENADINE;

ALLERGIC RHINITIS; ARTICLE; CHRONIC URTICARIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; ORAL DRUG ADMINISTRATION; QT INTERVAL;

EID: 0031807087     PISSN: 03445062     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Balcer S.L., M.S. Baker, C.L. Bugos et al.: In: Hoechst Marion Roussel (Hrsg.): Comparison of fexofenadine (F), terfenadine (T), loratadine (L) and placebo (P) in a double-blind crossover trial utilizing a skin test model to examine suppression of histamine-induced wheal and flare. 1997.
2. Ciprandi G., S. Buscaglia, G.P. Pesce, C. Pronzato, V. Ricca, S. Parmiani et al.: Minimal persistent inflammation is present at mucosal level in patients with asymptomatic rhinitis and mite allergy. J. Allergy Clin. Immunol. 96, 971-979 (1995).
3. Davalia J.L., M.M. Abdelaziz, H. Bayram et al.: In: Hoechst Marion Roussel (Hrsg.): Effect of fexofenadine on eosinophil-induced changes in epithelial permeability and mediator release from nasal epithelial cells of seasonal allergic rhinitis. 1997.
4. Dockhorn R.J , E.K. Hill, K.B. Hafner et al.: In: Hoechst Marion Roussel (Hrsg.): The duration of inhibition of skin prick test reactions after bid administration to steady-state of the non-sedating antihistamine fexofenadine HCL. 1997.
5. The effect of terfenadine acid metabolite (TAM) in airway inflammation and airway hyper-responsiveness (AHR) in ovalbumin (OA) sensitized mice. Abstract. San Francisco, 1997, 16.
6. Lippert C., N. Rao, M. Eller et al.: Pharmacokinetics of fexofenadine in liver diseased patients. Abstract. Pharm. Res. 13 (Suppl. 9), 131 (1996).
7. Markham A., A.J. Wagstaff: Fexofenadine. Drugs 55, 269-274 (1998).
8. Nakashima T., C.P. Kimmelman, J.B. Snow: Structure of human fetal and adult olfactory neuroepithelium. Arch. Otorhinolaryngol. 110, 641-646 (1984).
9. Paolieri F., A.M. Riccio, M. Battiforo et al.: MDL 16455 A and terfenadine in vitro activity on human continuous cell lines. Abstract. Allergy 30 (Suppl. 26), 77- (1995).
10. Pratt C., J. Mason, T. Russel et al.: In: Hoechst Marion Roussel (Hrsg.): Effect of fexofenadine HCL on corrected QT interval (QTc). 1997.
11. Rao N., D.R. Weilert, M.G.A. Grace et al.: Pharmacokinetics of terfenadine-acid-metabolite, MDL 16.455, in healthy geriatric subjects. Abstract. Pharm. Res. 12 (Suppl.), 386 (1995).
12. Russel T., T. Arumugham, M. Eller et al.: A comparison of MDL 16.455 A pharmacokinetics by gender. Abstract. Pharm. Res. 12 (Suppl.), (1995).
13. 1-blockade effect of fexofenadine. Ann. Allergy Asthma Immunol. 79, 530-532 (1997).
14. Stern M., J. Berth-Jones: In: Hoechst Marion Roussel (Hrsg.): Efficacy, tolerability and optimal dose of fexofenadine in chronic idiopathic urticaria. 1997.
15. Fexofenadine HCL versus cetirizine as a once daily treatment of seasonal allerig rhinitis. Manchester, 1996.
16. Evaluation of quality of life and health economic measures in patients treated with fexofenadine HCL for seasonal allergic rhinitis. Boston, 1996.
17. Tinkelman D., C. Falliers, E. Bronsky et al.: Efficacy and safety of fexofenadine HCL in fall seasonal allergic rhinitis. Abstract. J. Allergy Clin. Immunol. 97 (Pt 3), 435 (1996).